![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B + RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B + RIBAVRIN IN TREATMENT-NA&x#207;VE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A)
|
|
|
Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
![](../images/042410/042210-5/image002.gif)
![](../images/042410/042210-5/image004.gif)
![](../images/042410/042210-5/image006.gif)
![](../images/042410/042210-5/image008.gif)
Inclusion/Exclusion Criteria
![](../images/042410/042210-5/image010.gif)
![](../images/042410/042210-5/image012.gif)
![](../images/042410/042210-5/image014.gif)
![](../images/042410/042210-5/image016.gif)
![](../images/042410/042210-5/image018.gif)
![](../images/042410/042210-5/image020.gif)
![](../images/042410/042210-5/image022.gif)
![](../images/042410/042210-5/image024.gif)
![](../images/042410/042210-5/image026.gif)
![](../images/042410/042210-5/image028.gif)
![](../images/042410/042210-5/image030.gif)
480 STUDY Panel A: Injection Site Reaction Signs As Recorded By Investigators
![](../images/042410/042210-5/image032.gif)
![](../images/042410/042210-5/image034.gif)
![](../images/042410/042210-5/image036.gif)
![](../images/042410/042210-5/image038.gif)
![](../images/042410/042210-5/image040.gif)
![](../images/042410/042210-5/image042.gif)
![](../images/042410/042210-5/image044.gif)
![](../images/042410/042210-5/image046.gif)
![](../images/042410/042210-5/image048.gif)
![](../images/042410/042210-5/image050.gif)
![](../images/042410/042210-5/image052.gif)
![](../images/042410/042210-5/image054.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|